P-ISSN 2587-2400 | E-ISSN 2587-196X

Volume: 4 Issue: 3 - 2020

REVIEW
How to Face with Minimally Invasive Abdominal Surgery During Covid19 Outbreak Surgical and Anesthesiological Concerns
Mirko Barone, Marco Prioletta, Luigi Guetti, Sonia Capone, Larissa Pereira Ghammachi, Massimo Ippoliti, Elena Carluccio, Massimo Cieri, Alessandro Marolla, Giuseppe Cipollone, Liberato Aceto, Ivan Dell Atti, Carmine Lanci Lanci, Salvatore Maurizio Maggiore, Felice Mucilli
doi: 10.14744/ejmo.2020.22984   Pages  181 -  184 
(Viewed: 5186)

RESEARCH ARTICLE
The Molecular Docking Study of Potential Drug Candidates Showing Anti-COVID-19 Activity by Exploring of Therapeutic Targets of SARS-CoV-2
Rohan R. Narkhede, Rameshwar S. Cheke, Jaya P Ambhore, Sachin D. Shinde
doi: 10.14744/ejmo.2020.31503   Pages  185 -  195 
(Viewed: 8327)

IN Silico Approach of Some Selected Honey Constituents as SARS-CoV-2 Main Protease (COVID-19) Inhibitors
Heba E. Hashem
doi: 10.14744/ejmo.2020.36102   Pages  196 -  200 
(Viewed: 6603)

Epitope-Based Vaccine Design against Novel Coronavirus SARS-CoV-2 Envelope Protein
Hanuman Singh Dagur, Saurabh Singh Dhakar, Apporva Gupta
doi: 10.14744/ejmo.2020.01978   Pages  201 -  208 
(Viewed: 3409)

Immunotherapy in Geriatric Patients With Advanced Cancer
Birol Yildiz, Ramazan Acar
doi: 10.14744/ejmo.2020.44446   Pages  209 -  214 
(Viewed: 1671)

The Relationship Between Primary Tumor Localization and Driver Mutation in Lung Cancer
Cengiz Karacin, Tulay Eren, Goksen Inanc Imamoglu, Sema Turker, Fevzi Coskun Sokmen, Mustafa Altinbas
doi: 10.14744/ejmo.2020.13543   Pages  215 -  218 
(Viewed: 2145)

Hydroxychloroquine as Potent Inhibitor of COVID -19 Main Protease: Grid Based Docking Approach
Jitender Kumar Malik, Himesh Soni, Sarvesh Sharma, Satish Sarankar
doi: 10.14744/ejmo.2020.91607   Pages  219 -  226 
(Viewed: 7000)

Health-Related Quality of life of Patients Surgically Treated for benign Oral and Maxillofacial Tumours and Tumour-like lesions at Muhimbili National Hospital, Tanzania
Nalumino Sayela, Sira Stanslaus Owibingire, Boniphace M Kalyanyama, Karpal Singh Sohal
doi: 10.14744/ejmo.2020.42784   Pages  227 -  233 
(Viewed: 1856)

Bioinformatics Approach for COVID-19 (Coronavirus) Disease Prevention Treatment and Drug Validation
Shruti Mishra, Prashant Ankur Jain, Shmmon Ahmad, Shivam Mishra
doi: 10.14744/ejmo.2020.97358   Pages  234 -  238 
(Viewed: 3267)

CASE REPORT
Neck Metastasis of Glioblastoma: Rare Case
Andina Wirathmawati, Yuyun Yueniwati, Dessika Rahmawati, Eko Arisetijono Marhaendraputro, Shahdevi Nandar Kurniawan
doi: 10.14744/ejmo.2020.28152   Pages  239 -  245 
(Viewed: 2093)

Pneumocystis Jiroveci Mimicking COVID-19 Pneumonia in a Patient who is Receiving Ipilimumab and Nivolumab Combination Therapy: A Case Report
Elissar Moujaess, Elias El Haddad, Joseph Kattan
doi: 10.14744/ejmo.2020.89845   Pages  246 -  250 
(Viewed: 4233)

LETTER TO THE EDITOR
COVID-19 Outbreak: How to Use Current Knowledge to better Treat Positive Patients
Massimo Bonucci
doi: 10.14744/ejmo.2020.40842   Pages  251 -  252 
(Viewed: 4618)

A Response to Massimo Bonucci’s Editorial: COVID-19 Outbreak: How to Use Current Knowledge to Better Treat Positive Patients
Leung Ping-chung
doi: 10.14744/ejmo.2020.46269   Pages  253 -  255 
(Viewed: 3305)

Novel Coronavirus Disease (COVID-19): World’s Past Experience on Deadly Outbreaks
Temesgen A. Gelaw, Biniam M. Eskeziaw, Awoke Y. Dagnaw, Abeba H. Mariamenatu, Abreham C. Alemu, Gebiru S. Wondie, Meskerem K. Meles
doi: 10.14744/ejmo.2020.93695   Pages  256 -  259 
(Viewed: 3047)

COVID-19 Imaging in a Tertiary Care Setting – The Zurich Approach
Victor Mergen, Annelies Zinkernagel, Dagmar I. Keller, Thomas Frauenfelder, Hatem Alkadhi, Andreas Boss
doi: 10.14744/ejmo.2020.68370   Pages  260 -  263 
(Viewed: 2536)

WEB OF SCIENCE click

  • Impact Factor: 0.8

  • Medicine, General & Internal: Q2 146/322


  • SCOPUS click

  • CiteScoreTracker 2023: 5.6
  • CiteScore year 2022:
    0.9
  • CiteScore year 2021:
    0.2


  • Google Scholar click

  • Number of Articles:315
  • Citations:2587
  • h-index:16
  • i10-index:=26

  • EJMO NLM ID: 101720527

  • Accept Ratio :18.2 %
  • Final decision avg 34 day
  • EJMO & EJMO